BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29977173)

  • 1. Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.
    Vorobyeva A; Bragina O; Altai M; Mitran B; Orlova A; Shulga A; Proshkina G; Chernov V; Tolmachev V; Deyev S
    Contrast Media Mol Imaging; 2018; 2018():6930425. PubMed ID: 29977173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.
    Vorobyeva A; Sсhulga A; Konovalova E; Güler R; Mitran B; Garousi J; Rinne S; Löfblom J; Orlova A; Deyev S; Tolmachev V
    Int J Oncol; 2019 Apr; 54(4):1209-1220. PubMed ID: 30968147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins
    Larkina M; Varvashenya R; Yuldasheva F; Plotnikov E; Bezverkhniaia E; Tretyakova M; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Belousov M; Orlova A; Tolmachev V; Deyev S
    Mol Pharm; 2024 Apr; 21(4):1919-1932. PubMed ID: 38557163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1.
    Vorobyeva A; Bezverkhniaia E; Konovalova E; Schulga A; Garousi J; Vorontsova O; Abouzayed A; Orlova A; Deyev S; Tolmachev V
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33066684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect Radioiodination of DARPin G3 Using N-succinimidyl-
    Vorobyeva A; Schulga A; Rinne SS; Günther T; Orlova A; Deyev S; Tolmachev V
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.
    Deyev S; Vorobyeva A; Schulga A; Proshkina G; Güler R; Löfblom J; Mitran B; Garousi J; Altai M; Buijs J; Chernov V; Orlova A; Tolmachev V
    Mol Pharm; 2019 Mar; 16(3):995-1008. PubMed ID: 30608701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [
    Facca VJ; Al-Saden N; Ku A; Reilly RM
    Mol Imaging Biol; 2021 Aug; 23(4):495-504. PubMed ID: 33479914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and
    Okarvi SM; Aljammaz I
    Anticancer Res; 2018 May; 38(5):2823-2830. PubMed ID: 29715105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct In Vivo Comparison of
    Tolmachev V; Bodenko V; Oroujeni M; Deyev S; Konovalova E; Schulga A; Lindbo S; Hober S; Bragina O; Orlova A; Vorobyeva A
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
    Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
    J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal composition and position of histidine-containing tags improves biodistribution of
    Vorobyeva A; Schulga A; Konovalova E; Güler R; Löfblom J; Sandström M; Garousi J; Chernov V; Bragina O; Orlova A; Tolmachev V; Deyev SM
    Sci Rep; 2019 Jun; 9(1):9405. PubMed ID: 31253840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with
    Larkina M; Plotnikov E; Bezverkhniaia E; Shabanova Y; Tretyakova M; Yuldasheva F; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Garousi J; Gräslund T; Belousov M; Tolmachev V; Deyev S
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
    Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
    J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
    Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
    J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.
    Okarvi SM; AlJammaz I
    Molecules; 2019 Aug; 24(17):. PubMed ID: 31470531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of
    Rainone P; Riva B; Belloli S; Sudati F; Ripamonti M; Verderio P; Colombo M; Colzani B; Gilardi MC; Moresco RM; Prosperi D
    Int J Nanomedicine; 2017; 12():3447-3461. PubMed ID: 28496321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging.
    Goldstein R; Sosabowski J; Livanos M; Leyton J; Vigor K; Bhavsar G; Nagy-Davidescu G; Rashid M; Miranda E; Yeung J; Tolner B; Plückthun A; Mather S; Meyer T; Chester K
    Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):288-301. PubMed ID: 25391547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
    Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
    Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
    Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
    Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Trial of
    Bragina O; Chernov V; Schulga A; Konovalova E; Garbukov E; Vorobyeva A; Orlova A; Tashireva L; Sörensen J; Zelchan R; Medvedeva A; Deyev S; Tolmachev V
    J Nucl Med; 2022 Apr; 63(4):528-535. PubMed ID: 34385343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.